Updates are available Correction dated 2022-09-01
Click to view Correction: https://doi.org/10.1038/s41586-022-05287-8
-
Authors
Zingg, Daniel http://orcid.org/0000-0001-6450-2534
Bhin, Jinhyuk http://orcid.org/0000-0001-8898-4531
Yemelyanenko, Julia http://orcid.org/0000-0001-9697-2039
Kas, Sjors M.
Rolfs, Frank
Lutz, Catrin
Lee, Jessica K. http://orcid.org/0000-0002-4333-5092
Klarenbeek, Sjoerd http://orcid.org/0000-0002-1891-1940
Silverman, Ian M. http://orcid.org/0000-0003-3819-6726
Annunziato, Stefano
Chan, Chang S. http://orcid.org/0000-0001-9897-4759
Piersma, Sander R.
Eijkman, Timo
Badoux, Madelon
Gogola, Ewa
Siteur, Bjørn
Sprengers, Justin
de Klein, Bim
de Goeij-de Haas, Richard R.
Riedlinger, Gregory M.
Ke, Hua
Madison, Russell http://orcid.org/0000-0002-7838-2526
Drenth, Anne Paulien
van der Burg, Eline
Schut, Eva
Henneman, Linda
van Miltenburg, Martine H.
Proost, Natalie
Zhen, Huiling
Wientjens, Ellen
de Bruijn, Roebi
de Ruiter, Julian R.
Boon, Ute
de Korte-Grimmerink, Renske
van Gerwen, Bastiaan
Féliz, Luis http://orcid.org/0000-0003-0659-229X
Abou-Alfa, Ghassan K.
Ross, Jeffrey S.
van de Ven, Marieke
Rottenberg, Sven http://orcid.org/0000-0003-2044-9844
Cuppen, Edwin
Chessex, Anne Vaslin
Ali, Siraj M. http://orcid.org/0000-0001-7477-4023
Burn, Timothy C. http://orcid.org/0000-0001-6648-4333
Jimenez, Connie R.
Ganesan, Shridar
Wessels, Lodewyk F. A. http://orcid.org/0000-0002-1656-6995
Jonkers, Jos http://orcid.org/0000-0002-9264-9792
- License Information
-
More Information
Article History
Received: 19 January 2021
Accepted: 3 July 2022
First Online: 10 August 2022
Change Date: 1 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-05287-8
Competing interests
: J.K.L. and R.M are employees of Foundation Medicine and have equity in Roche. I.M.S., H.Z., L.F. and T.C.B. are employees of and have equity in Incyte. G.K.A.-A. has performed research for ActaBiologica, Agios, Astra Zeneca, Bayer, Beigene, Berry Genomics, BMS, Casi, Celgene, Exelixis, Genentech/Roche, Halozyme, Incyte, Mabvax, Puma, QED, Sillajen and Yiviva, and has consulted for Agios, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Debio, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Gilead, Helio, Incyte, Ipsen, Loxo, Merck, MINA, Polaris, QED, Redhill, Silenseed, Sillajen, Sobi, Therabionics, Twoxar, Vector and Yiviva. J.S.R. is an employee of Foundation Medicine, has equity in Roche and is a board member of Celsius Therapeutics. A.V.C. is an employee of Debiopharm International. S.M.A. is an employee of and has equity in EQRX, is a former employee of Foundation Medicine, is a scientific advisory board member of iN Therapeutics and has consulted for Takeda. S.G. has received research funding from M2Gen, has equity in Inspirata and Silagene, and has consulted for Foghorn Therapeutics, Foundation Medicine, Inspirata, Merck, Novartis, Roche and Silagene; his spouse is an employee of and has equity in Merck. The other authors declare no competing interests.
